



From: Barrett Land
 To: Office of the Vermont Attorney General
 CC: Patricia Guedea
 Date: June 13, 2019


Subject: Notice of New Prescription Drug Pursuant to 18 V.S.A § 4637


Greenwich Biosciences, Inc. (“Greenwich”) issues this notice pursuant to 18 V.S.A § 4637.

It has recently come to our attention that Greenwich inadvertently did not provide notification of Epidiolex’s commercial release to the Vermont Attorney General. Greenwich released Epidiolex® (cannabidiol) CV into the commercial market on November 1, 2018.

Epidiolex’s NDC#: 70127-100-10 WAC: \$1,235.00

Statutory Requirement	Reporting Information
A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally.	Pursuant to 18 V.S.A. § 4637(d), we may limit the information reported to that which is in the public domain or publicly available. This information is not publicly available and has not been released in the public domain.
The estimated volume of patients that may be prescribed the drug.	Pursuant to 18 V.S.A. § 4637(d), we may limit the information reported to that which is in the public domain or publicly available. The estimated national volume of patients who might be prescribed Epidiolex is not in the public domain or publicly available.
Was the drug granted breakthrough therapy designation by the federal Food and Drug Administration (FDA) prior to final approval?	Epidiolex’s approval was the FDA's first for a drug utilized to treat Dravet syndrome, a rare and severe type of epilepsy. Epidiolex is the first FDA-approved prescription pharmaceutical formulation of plant-derived cannabidiol (CBD).
Did the drug receive a priority review by the federal FDA prior to final approval?	Prior to final approval, Epidiolex received priority review through Fast Track designation by the FDA.
The date and price of acquisition if the drug was not developed by the manufacturer.	N/A- Epidiolex was developed by Greenwich and its affiliates.


 Barrett J. Land
 Sr. Director US Pricing and Trade
 Greenwich Biosciences, Inc.


 Date: